Treats moderately to severely active rheumatoid arthritis (RA). Sold as Orencia. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Abatacept (sold as Orencia), first approved Dec 23, 2005, with 10 new uses approved and 0 published complete response letters.
| Orencia | Part B | $961M | +3% | 34,137 |
| Orencia Clickject | Part D | $853M | +50% | 18,863 |
| Orencia | Part D | $329M | +32% | 8,015 |
| A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male ParticipantsHealthy Volunteers · Dr. Reddy's Laboratories Limited, India | Phase 1 | Not yet recruiting | Aug 4, 2026 |
| PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCTGVHD - Graft-Versus-Host Disease · Northwell Health | Phase 1 / Phase 2 | Recruiting | Jun 30, 2026 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseSickle Cell Disease · St. Jude Children's Research Hospital | Phase 2 | Recruiting | Jun 1, 2026 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsSickle Cell Disease, Beta-thalassemia · National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 | Recruiting | May 20, 2026 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaLymphoma, T Cell, Peripheral, T-cell Lymphoma · National Cancer Institute (NCI) | Phase 1 | Recruiting | Feb 5, 2026 |
| Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesAcute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk · Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 | Recruiting | Jan 26, 2026 |
| Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorAcute Myeloid Leukemia (AML), Chronic Myeloid Leukemia · St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Nov 20, 2025 |
| Study of COYA 302 for the Treatment of ALSAmyotrophic Lateral Sclerosis (ALS) · Coya Therapeutics | Phase 2 / Phase 3 | Active, not recruiting | Sep 9, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 23, 2005 | OrenciaBLA 125118 · New molecular entity | Bristol Myers Squibb | 23 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bristol Myers Squibb